Among women with mutations in BRCA1 or BRCA2, oophorectomy reduces the risk of developing ovarian, fallopian tube, or peritoneal cancer by 80 percent.
Intravenous ascorbate (vitamin C) seems beneficial in ovarian cancer, inducing cell death in vitro and reducing chemotherapy-associated toxicity in vivo.
A study of almost 20,000 women found the drug lowered ovarian cancer risk by 20 percent.
A new study conservatively estimates that 1 in 5 women with ovarian cancer have inherited genetic mutations that increase the risk of the disease.
An investigational new PARP inhibitor, BMN 673, is showing early responses in patients with advanced, BRCA-related breast and ovarian cancers.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|